Entries by CAPTIS

Limelight Bio emerges with $75m to develop next generation gene therapies to overcome limitations of current treatments

Founded in 2017, Limelight Bio has developed proprietary technologies, advanced targets and leading drug candidates designed to overcome key limitations of current gene therapy and gene editing approaches. The post Limelight Bio emerges with $75m to develop next generation gene therapies to overcome limitations of current treatments appeared first on Pharmaceutical Business review.

Meitheal Pharmaceuticals announces FDA approval of Enoxaparin Sodium Injection, USP

Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (NKF), its majority shareholder. Enoxaparin had annual sales of approximately $616M in The post Meitheal Pharmaceuticals announces FDA approval of Enoxaparin Sodium Injection, USP appeared first on Pharmaceutical Business review.

AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations

This enterprise-wide data and analytics platform is expected to form the foundation for custom solutions powered by AWS AI and ML services to help drive agility, innovation, and The post AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations appeared first on Pharmaceutical Business review.

Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS

Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will hold a review The post Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS appeared first on Pharmaceutical Business review.

IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets

The agreement is to generate and optimise antibodies for novel immuno-oncology targets, including access to IONTAS’ proprietary Mammalian Display technology to select antibodies with optimal biophysical properties. IONTAS’ The post IONTAS and Adaptate Biotherapeutics collaborate to identify optimised antibodies for novel cancer targets appeared first on Pharmaceutical Business review.